Combining a vaccine and immunotherapy approach could open new ways to treat cancer.

The rally was primarily driven by the strong late-stage trial of Moderna Inc.’s (NASDAQ:MRNA) intismeran autogene—an ...

Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment ...

Drug company stocks soared following news that Moderna and Merck’s experimental mRNA-based cancer vaccine succeeded in a late ...

CBS News medical correspondent Dr. Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big ...

The announcement by Moderna Inc. and Merck & Co. that a messenger RNA-based cancer vaccine had lowered the recurrence rate ...

Health officials say a potential new weapon in the fight against melanoma is showing promising results. Moderna and Merck say ...

"These corporations have learned how to play the medical-scientific establishment like a Stradivarius," Johns Hopkins ...

Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the ...

Doctors and patients are excited about the possible breakthrough, but some analysts believe there’s too much hype.

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 20% in the morning session after investors took profits as the ...

The biggest positive for Moderna, Inc. (NASDAQ:MRNA) is that Intismeran could become the product that changes the company’s ...